相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
Niccolo Giaj-Levra et al.
LUNG CANCER (2020)
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
Shuling Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
Relinde I. Y. Lieverse et al.
MOLECULAR ONCOLOGY (2020)
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Yolande Lievens et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study
Oscar Arrieta et al.
LUNG CANCER (2019)
Radiation and immunotherapy to fight cancer: a 'pushing the gas and releasing the brakes' approach.
V. Olivo Pimentel et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review
Niccolo Giaj-Levra et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Benjamin Weide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C. Dingemans et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
Antonin Levy et al.
EUROPEAN JOURNAL OF CANCER (2019)
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion
Lizza E. L. Hendriks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome
Ahmed Salem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome
Ahmed Salem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer
Kevin Jao et al.
LUNG CANCER (2018)
High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer
Penny Fang et al.
RADIOTHERAPY AND ONCOLOGY (2018)
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Nicolle H. Rekers et al.
ONCOIMMUNOLOGY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment
Jinhuo Lai et al.
ONCOTARGETS AND THERAPY (2018)
High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions
Stephen Marabondo et al.
EXPERT OPINION ON DRUG SAFETY (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
Radiotherapy for Oligometastatic Lung Cancer
Derek P. Bergsma et al.
FRONTIERS IN ONCOLOGY (2017)
Neutrophils, a candidate biomarker and target for radiation therapy?
Antoine Schernberg et al.
ACTA ONCOLOGICA (2017)
Quality assessment of positron emission tomography scans: recommendations for future multicentre trials
Evelyn E. C. de Jong et al.
ACTA ONCOLOGICA (2017)
Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis
Andrea Lancia et al.
ACTA ONCOLOGICA (2017)
Combining radiotherapy with immunotherapy: the past, the present and the future
Evert J. Van Limbergen et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11)
Sridharan Gururangan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
Michel M. van den Heuvel et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
Nicolle H. Rekers et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M. L. Zegers et al.
CLINICAL CANCER RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Stereotactic body radiotherapy for multisite extracranial oligometastases Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
Joseph K. Salama et al.
CANCER (2012)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Thomas K. Eigentler et al.
CLINICAL CANCER RESEARCH (2011)
PREDICTORS OF LOCAL CONTROL AFTER SINGLE-DOSE STEREOTACTIC IMAGE-GUIDED INTENSITY-MODULATED RADIOTHERAPY FOR EXTRACRANIAL METASTASES
Carlo Greco et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control
Michelle A. Stinauer et al.
RADIATION ONCOLOGY (2011)
Oligometastases confined one organ from colorectal cancer treated by SBRT
Jin-Kyu Kang et al.
CLINICAL & EXPERIMENTAL METASTASIS (2010)
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
Manfred Johannsen et al.
EUROPEAN JOURNAL OF CANCER (2010)
Stereotactic body radiation therapy: The report of AAPM Task Group 101
Stanley H. Benedict et al.
MEDICAL PHYSICS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy
Bernard M. Tijink et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions
Michael T. Milano et al.
CANCER (2008)
ED-B fibronectin in non-small cell lung carcinoma
ZA Khan et al.
EXPERIMENTAL LUNG RESEARCH (2005)
ED-B fibronectin as a target for antibody-based cancer treatments
A Menrad et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Diagnostic and therapeutic applications of recombinant antibodies: Targeting the extra-domain B of fibronectin, A marker of tumor angiogenesis
C Ebbinghaus et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors
MT Birchler et al.
LARYNGOSCOPE (2003)
分享论文
